Consolidated revenue was at R1,381.25 crore against R1,031.08 crore in the corresponding period last year, an increase of 33.96%. Excluding out-licensing income received in the third quarter, Glenmarks consolidated revenue for the third quarter grew by 32.24%. Revenue from the generics business was at R580.98 crore, against R436.83 crore, a growth of 33%.
The specialty formulation business, excluding out-licensing revenue, was at R735.76 crore against R560.69 crore for the corresponding previous quarter, a growth of 31.22%. Share of the company were trading flat on the BSE on Tuesday and closed at R504.05.